Palliative Bladder Radiation: 21 Gy in 3 Fractions Scheduling
For a palliative bladder radiation regimen of 21 Gy in 3 fractions, deliver the treatment on consecutive days (daily schedule) rather than every other day.
Rationale for Daily Delivery
The 21 Gy/3 fraction regimen is a well-established hypofractionated palliative schedule for symptomatic bladder cancer, and the evidence supports consecutive daily delivery:
The landmark MRC BA09 trial 1 established 21 Gy in 3 fractions as equally effective to 35 Gy in 10 fractions for symptomatic improvement (68% overall response rate), with no difference in survival or toxicity. This trial used consecutive daily fractions delivered over 3 days.
Hypofractionated regimens are specifically designed for rapid symptom relief in palliative settings 2. The biological rationale for large fraction sizes (7 Gy per fraction) is to achieve quick tumor response for bleeding, pain, and urinary symptoms. Spreading these fractions over a longer period dilutes this advantage.
The 21 Gy/3 fraction schedule provides symptom relief within weeks 2, with particularly strong efficacy for hematuria (74% pooled response rate) and frequency symptoms (71% response rate) 3. Daily delivery maximizes the speed of symptom control, which is the primary goal in palliative care.
Clinical Context
The systematic review by 3 demonstrated that while higher total doses were associated with longer duration of hematuria response, they did not improve initial response rates for hematuria or frequency symptoms. This supports using efficient delivery schedules for the 21 Gy regimen.
Important caveat: One study 4 used 17 Gy in 2 fractions over 3 days (implying a day gap), but this was a different dose schedule. The standard 21 Gy/3 fraction protocol follows consecutive daily delivery.
Practical Considerations
- Patient convenience: Three consecutive days minimizes treatment burden and travel for palliative patients who often have poor performance status
- Toxicity profile: Grade 3 gastrointestinal and genitourinary toxicity occurs in up to 26% of patients 3, but this is not increased by daily delivery
- Treatment completion: Given that 14% of palliative patients fail to complete planned treatment 5, minimizing the treatment window improves completion rates
The NCCN guidelines 6 specifically note that chemotherapy should not be used concurrently with high-dose (>3 Gy per fraction) palliative radiation, which applies to this 7 Gy per fraction regimen, regardless of daily versus alternate-day scheduling.